Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
Part of paid clinical trials in Philadelphia, Pennsylvania.
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
- Study ID
- NCT03495024
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Parkinsonism
- Schizoaffective Disorder
- Schizophrenia
- Tardive Dyskinesia
- Tobacco Smoking
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Varenicline — DRUGOral medication approved to facilitate smoking cessation
Study Details
To test the feasibility of studying effects of smoking cessation with varenicline on antipsychotic drug-induced neurological side effects, we propose a 12 week pilot study of smoking cessation treatment with varenicline in 10 schizophrenia or schizoaffective disorder patients who are actively smoking and have pre-existing TD while receiving stable doses of antipsychotics. Subjects will be followed after a 2 week baseline period to assess changes in smoking status and neurological symptoms using standardized rating scales. The aim is to examine clinically significant effects on antipsychotic-induced neurological side effects that may warrant further investigation.
Key Dates
- Start date
- Jan 1, 2019
- Status verified
- Mar 2019
- Primary completion
- Apr 30, 2020
- Completion
- Jun 30, 2020
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Other: Smoking cessation with vareniclineFDA-approved indication of varenicline for smoking cessation
Primary Outcome Measure
Self-reported 7-day point prevalence of abstinence prior to week 12 [ Time Frame: 12 weeks ]
Central Contacts
- Stanley N Caroff, MD215-823-4065
- Rosalind M Berkowitz, MD215-823-4065
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Corporal Michael J Crescenz VA Medical Center | Philadelphia | Pennsylvania | 19104 |
Find similar trials in Philadelphia, PA
Related Studies
- Zyprexa® Relprevv™ Patient Care ProgramEnrolling By Invitation · Eli Lilly and Company · Blue Bell, Pennsylvania
- Bromocriptine for Patients With Schizophrenia and PrediabetesPHASE4 · Not Yet Recruiting · VA Pittsburgh Healthcare System · Pittsburgh, Pennsylvania
- Cromoglicate Adjunctive Therapy for Outpatients With SchizophreniaPHASE1/PHASE2 · Recruiting · Vishwajit Nimgaonkar, MD PhD · Pittsburgh, Pennsylvania
- Acetazolamide for Treatment Resistant SchizophreniaPHASE1/PHASE2 · Recruiting · Vishwajit Nimgaonkar, MD PhD · Pittsburgh, Pennsylvania